Try our mobile app
Screener

Reviews

2024-05-15
#reports #VRME

[VerifyMe](https://eninvs.com/all.php?name=VRME) (Security and Protection Services) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=VRME&q=2024 q1&id=781855)
(2024-05-14, Before Market Open):

- Revenue 0.0% YoY (vs -10.0% in previous quarter and historical rate +69.6%)
- EBITDA 0.0% YoY (vs -14.3% in previous quarter)
- EBITDA margin 50.0% has not changed compared to 50.0% same period last year
- EV/Sales multiple is 0.7x

2024-05-15
#reports #UNB

[Union Bankshares](https://eninvs.com/all.php?name=UNB) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169477)
(2024-04-17, After Market Close):

- Revenue -10.0% YoY (vs -10.0% in previous quarter and historical rate -8.3%)
- Net Income -33.3% YoY (vs +500.0% in previous quarter and historical rate -3.3%)
- Net Income margin 22.2% decreased compared to 30.0% same period last year
- P/E multiple is 10.5x compared to historical level (75th percentile) of 24.8x
- P/S multiple is 3.1x
- Price to book: 1.8x

The company showed EPS +$0.53 per share. At the opening of the session the share price went up +0.1% vs S&P500 +0.2%
2024-05-15
#reports #TISI

[Team](https://eninvs.com/all.php?name=TISI) (Specialty Business Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169476)
(2023-05-11, After Market Close):

- Revenue -1.0% YoY (vs +1.4% in previous quarter and historical rate +2.4%)
- Net Income margin -8.5% increased compared to -12.4% same period last year
- P/S multiple is 0.0x
- Price to book: 0.6x

At the opening of the session the share price went down -0.2% vs S&P500 +0.2%
2024-05-15
#reports #STRS

[Stratus Properties](https://eninvs.com/all.php?name=STRS) (Real Estate — Diversified) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169472)
(2024-05-13, Before Market Open):

- Revenue +150.0% YoY (vs -69.2% in previous quarter and historical rate +7.8%)
- EBITDA margin 106.7% increased compared to -83.3% same period last year
- EV/EBITDA multiple is 45.1x compared to historical level (75th percentile) of 81.6x
- EV/Sales multiple is 15.0x

The company showed EPS +$0.56 per share. At the opening of the session the share price went down -4.7% vs S&P500 +0.2%
2024-05-15
#reports #SSTI

[ShotSpotter](https://eninvs.com/all.php?name=SSTI) (Software — Application) reported for 2024 q1
(2024-05-14, After Market Close):

- Revenue +19.0% YoY (vs -67.9% in previous quarter and historical rate +30.7%)
- Net Debt decreased by $3.0 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.4% of market cap
- EV/EBITDA multiple is 24.8x compared to historical level (75th percentile) of 67.6x
- EV/Sales multiple is 1.8x

2024-05-15
#reports #PXLW

[Pixelworks](https://eninvs.com/all.php?name=PXLW) (Semiconductors) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=PXLW&q=2024 q1&id=781900)
(2024-05-14, After Market Close):

- Revenue +60.0% YoY (vs +17.6% in previous quarter and historical rate +29.7%)
- EBITDA margin -25.0% increased compared to -90.0% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 11.3% of market cap
- EV/Sales multiple is 1.7x

2024-05-15
#reports #PRPO

[Precipio](https://eninvs.com/all.php?name=PRPO) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169505)
(2023-11-13, After Market Close):

- Revenue 0.0% YoY (vs +33.3% in previous quarter and historical rate +48.6%)
- EBITDA margin -33.3% increased compared to -66.7% same period last year
- EV/Sales multiple is 9.9x

At the opening of the session the share price went down -7.1% vs S&P500 +1.0%
2024-05-15
#reports #POAI

[Predictive Oncology](https://eninvs.com/all.php?name=POAI) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169528)
(2023-05-17, After Market Close):

- Revenue +75.0% YoY (vs -7.7% in previous quarter and historical rate +79.7%)
- EBITDA margin -970.0% decreased compared to -22.5% same period last year
- Net Debt increased by $3.4 bln over the past reporting period (2709.1% of market cap)
- FCF (LTM) -$13.7 bln (negative), 10817.5% of market cap
- EV/EBITDA multiple is 0.3x compared to historical level (75th percentile) of 1.5x
- EV/Sales multiple is -2.3x

2024-05-15
#reports #PMD

[Psychemedics Corporation](https://eninvs.com/all.php?name=PMD) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169480)
(2024-05-13, Before Market Open):

- Revenue -16.7% YoY (vs -16.7% in previous quarter and historical rate +9.8%)
- EBITDA margin -20.0% decreased compared to -16.7% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (6.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 6.8% of market cap
- EV/Sales multiple is 0.7x

2024-05-15
#reports #PBH

[Prestige Consumer Healthcare](https://eninvs.com/all.php?name=PBH) (Medicines manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=PBH&q=2024 q1&id=781897)
(2024-05-14, After Market Close):

- Revenue -3.1% YoY (vs +2.5% in previous quarter and historical rate +6.3%)
- EBITDA margin 32.5% increased compared to -95.5% same period last year
- Net Debt decreased by $56.0 mln over the past reporting period (1.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 5.2% of market cap
- EV/EBITDA multiple is 12.5x compared to historical level (75th percentile) of 466.6x
- EV/Sales multiple is 4.1x

On post-market the stock shows a decrease by -7.7%
2024-05-15
#reports #OVLY

[Oak Valley Bancorp](https://eninvs.com/all.php?name=OVLY) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169531)
(2024-04-18, Before Market Open):

- Revenue -15.0% YoY (vs -15.0% in previous quarter and historical rate +14.8%)
- Net Income -41.7% YoY (vs -33.3% in previous quarter and historical rate +46.6%)
- Net Income margin 41.2% decreased compared to 60.0% same period last year
- P/E multiple is 5.6x compared to historical level (75th percentile) of 8.2x
- P/S multiple is 2.8x
- Price to book: 1.2x

The company showed EPS +$0.69 per share. At the opening of the session the share price went up +0.3% vs S&P500 +0.2%
2024-05-15
#reports #NSYS

[Nortech Systems](https://eninvs.com/all.php?name=NSYS) (Electronic Components) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169412)
(2024-05-16, After Market Close):

- Revenue -2.9% YoY (vs 0.0% in previous quarter and historical rate +13.0%)
- EBITDA 0.0% YoY (vs -62.5% in previous quarter and historical rate +49.0%)
- EBITDA margin 5.9% increased compared to 5.7% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (4.8% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.8% of market cap
- EV/EBITDA multiple is 5.9x compared to historical level (75th percentile) of 4.8x
- EV/Sales multiple is 0.4x

The company showed EPS +$2942.31 per share
2024-05-15
#reports #NAII

[Natural Alternatives International](https://eninvs.com/all.php?name=NAII) (Packaged Foods) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169479)
(2024-05-13, After Market Close):

- Revenue -24.2% YoY (vs -40.5% in previous quarter and historical rate +6.5%)
- EBITDA margin -4.0% increased compared to -6.1% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (5.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 44.7% of market cap
- EV/EBITDA multiple is 10.1x compared to historical level (75th percentile) of 4.9x
- EV/Sales multiple is 0.4x

2024-05-15
#reports #MTEX

[Mannatech](https://eninvs.com/all.php?name=MTEX) (Household and Personal Products) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169389)
(2024-05-13, Before Market Open):

- Revenue -14.7% YoY (vs -2.9% in previous quarter and historical rate -0.2%)
- EBITDA margin 3.4% increased compared to 2.9% same period last year
- EV/EBITDA multiple is 1.7x compared to historical level (75th percentile) of 2.8x
- EV/Sales multiple is 0.1x

At the opening of the session the share price went down -7.4% vs S&P500 +0.2%
2024-05-15
#reports #IRIX

[IRIDEX Corporation](https://eninvs.com/all.php?name=IRIX) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=IRIX&q=2024 q1&id=781891)
(2024-05-14, After Market Close):

- Revenue -14.3% YoY (vs -20.0% in previous quarter and historical rate +10.9%)
- EBITDA margin -25.0% decreased compared to -14.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 12.0% of market cap
- EV/Sales multiple is 0.9x

2024-05-15
#reports #INTZ

[Intrusion](https://eninvs.com/all.php?name=INTZ) (Software — Infrastructure) reported for 2024 q1
(2024-05-15, After Market Close):

- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate -16.7%)
- EBITDA margin -200.0% increased compared to -400.0% same period last year
- EV/Sales multiple is 4.3x

2024-05-15
#reports #DMTK

[DermTech](https://eninvs.com/all.php?name=DMTK) (Medicine services provider) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DMTK&q=2024 q1&id=781886)
(2024-05-14, After Market Close):

- Revenue +33.3% YoY (vs +33.3% in previous quarter and historical rate +54.9%)
- EBITDA margin -475.0% increased compared to -1033.3% same period last year
- Net Debt increased by $16.0 mln over the past reporting period (72.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 216.8% of market cap
- EV/Sales multiple is 2.3x

2024-05-15
#reports #DCTH

[Delcath Systems](https://eninvs.com/all.php?name=DCTH) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DCTH&q=2024 q1&id=781831)
(2024-05-14, Before Market Open):

- Revenue +200.0% YoY (vs 0.0% in previous quarter and historical rate +62.5%)
- EBITDA margin -333.3% increased compared to -800.0% same period last year
- Net Debt increased by $7.0 mln over the past reporting period (4.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.5% of market cap
- EV/Sales multiple is 40.2x

At the opening of the session the share price went up +11.3% vs S&P500 0.0%
2024-05-15
#reports #BLIN

[Bridgeline Digital](https://eninvs.com/all.php?name=BLIN) (Software — Infrastructure) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BLIN&q=2024 q1&id=781878)
(2024-05-14, After Market Close):

- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +19.4%)
- EV/Sales multiple is 0.6x

2024-05-15
#reports #ACOR

[Acorda Therapeutics](https://eninvs.com/all.php?name=ACOR) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169502)
(2023-08-08, After Market Close):

- Revenue -9.1% YoY (vs +22.6% in previous quarter and historical rate -7.7%)
- EBITDA margin -95.0% decreased compared to -13.6% same period last year
- Net Debt increased by $26.0 mln over the past reporting period (161.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 248.6% of market cap
- EV/Sales multiple is 1.8x

At the opening of the session the share price went down -2.2% vs S&P500 0.0%
2024-05-15
#reports #AC

[Associated Capital Group](https://eninvs.com/all.php?name=AC) (Capital Markets) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=AC&q=2024 q1&id=780759)
(2024-05-09, After Market Close):

- Revenue +50.0% YoY (vs -25.0% in previous quarter and historical rate +1.3%)
- Net Income -22.2% YoY (vs +14.3% in previous quarter and historical rate -23.9%)
- Net Income margin 466.7% decreased compared to 900.0% same period last year
- P/E multiple is 25.2x compared to historical level (75th percentile) of 24.0x
- P/S multiple is 56.2x
- Price to book: 0.8x

The company showed EPS +$0.64 per share. At the opening of the session the share price went down -0.3% vs S&P500 +0.2%